KYNB — KYNTRA BIO, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 921299 ·
Last close
$6.90
Market Cap
$27.94M
52W High
$12.54
52W Low
$6.32
ADV30
24,904
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | -1,474,000 | -1,476,000 | -17,563,000 | 11,974,000 | 101,078,000 | 50,644,000 | 109,222,000 |
| Mar 2026 | 3,738,000 | -368,000 | -13,796,000 | -15,198,000 | 109,629,000 | 36,997,000 | 118,919,000 |
| Dec 2025 | 1,277,000 | 999,000 | -13,519,000 | -14,220,000 | 119,594,000 | 47,872,000 | 115,119,000 |
| Sep 2025 | 1,076,000 | 1,134,000 | -5,370,000 | 200,636,000 | 137,014,000 | 117,975,000 | 119,529,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,380,000
Investing CF
$38,453,000
Financing CF
$-85,947,000
CapEx
$-179,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$40.46
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,721,245,000
Inventory
$3,384,000
Receivables
$9,040,000
ST Investments
$50,240,000
EBIT TTM
$-47,731,000
Pretax Income TTM
$-56,663,000
Interest Exp TTM
$8,932,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,616,000
EBITDA
$-50,035,000
Free Cash Flow
$54,074,376
Enterprise Value
$-37,046,480
Total Cash
$91,318,000
Total Debt
$0
Shares Out
4,049,124
Trailing EPS
$-7.64
Book Value
$-7.45
ROE
—
ROA
-22.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,440,000 | -45,342,000 | 183,452,000 | 119,594,000 | 115,119,000 | -30,038,000 | -4,774,000 |
| Dec 2024 | 29,621,000 | -130,962,000 | -47,579,000 | 214,525,000 | 398,160,000 | -225,602,000 | -137,999,000 |
| Dec 2023 | 46,803,000 | -310,115,000 | -284,232,000 | 423,529,000 | 585,728,000 | -204,166,000 | -315,021,000 |
| Dec 2022 | 140,734,000 | -301,025,000 | -293,654,000 | 610,087,000 | 611,567,000 | -21,447,000 | -145,933,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-14.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABVC | ABVC BIOPHARMA, INC. | $27.99M | $1.05 | — |
| MDNAF | Medicenna Therapeutics Corp. | $27.87M | $0.30 | — |
| OPTH | Optimi Health Corp. | $27.77M | $4.85 | — |
| IGC | IGC Pharma, Inc. | $28.33M | $0.27 | — |
| CLCS | Cell Source, Inc. | $28.50M | $0.42 | — |
News headlines (Yahoo Finance, 1h cache)
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 11:30 · Yahoo
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
2026-08-31 20:05 · Yahoo
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript
2026-08-20 21:43 · Yahoo
Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advancing FG-3246 and Roxadustat with ...
2026-08-17 19:02 · Yahoo
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 21:35 · Yahoo
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 20:02 · Yahoo
Kyntra Bio to Report Second Quarter 2026 Financial Results
2026-08-06 13:00 · Yahoo
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
2026-08-03 14:00 · Yahoo
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
2026-06-11 20:05 · Yahoo
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-11 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.